Early safety study of IA-14069 in rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 1 study tests how safe and tolerable IA-14069 is. It includes people with rheumatoid arthritis (RA) and healthy volunteers, and may help researchers plan future RA treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18–55 years old (healthy volunteer part) or 18–70 years old (RA part).
- Have a body mass index (BMI) in the study’s allowed range and weigh at least 50 kg.
- If you’re in the RA part: have active RA, with enough swollen/tender joints and abnormal inflammation blood tests (CRP or ESR).
- If you have childbearing potential: you must not be pregnant and you must use effective birth control starting 4 weeks before dosing and for 90 days after the last dose.
- Avoid certain meds/supplements before dosing (including herbs like St. John’s wort) and avoid alcohol/caffeine rules while at the study site.
- For the RA part: you must be on a stable dose of methotrexate (MTX) for at least 12 weeks before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This early-phase study tests whether ZB002 is safe in people, and how the body handles the drug. It includes both healthy volunteers and people with rheumatoid arthritis (RA) to see if the drug has a predictable blood level pattern.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.